



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IFW/ 1643

Pre Patent Application of

HANAI et al

Atty. Ref.: 249-255

Serial No. 10/089,500

Group: 1643

Filed: March 29, 2002

Examiner: BLANCHARD, David J.

For: COMPLEMENTARY DETERMINING REGION-  
GRAFTED ANTIBODY AGAINST GANGLIOSIDE GD3  
AND DERIVATIVE OF ANTIBODY AGAINST  
GANGLIOSIDE GD3

\* \* \* \* \*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

September 15, 2005

Sir:

**INFORMATION DISCLOSURE STATEMENT**

- ☐ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**  
[within 3 months of filing or prior to 1st Office Action on the merits]  
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
\$180.00
- ☒ 3. **Pursuant to 37 CFR 1.97(d)**  
[after Final Office Action or Allowance (requires Rule 97(e)  
Statement and Rule 17(p) fee), but before final fee payment]  
\$180.00

The following are submitted in the above-identified application in compliance with  
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

- ☐ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☒ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☒ b) The required Statement is stated in item 8 below.
- ☒ 8. Statement under 37 CFR 1.97(e)
- ☒ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,  
NIXON & VANDERHYE P.C.

By: \_\_\_\_\_



B. J. Sadoff

Reg. No. 36,663

901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

## INFORMATION DISCLOSURE

## CITATION

ATTY. DOCKET NO.

SERIAL NO.

249-255

10/089,500

APPLICANT

ANAI et al

(Use several sheets if necessary)

FILING DATE

GROUP

March 29, 2002

1643

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,091,178	02/1992	Hellstrom et al.			
	5,730,981	03/1998	Bosslet et al.			
	5,610,280	03/1997	Brandt et al.			
	5,006,470	04/1991	Yamaguchi et al.			

## FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
0 280 209 A2	08/1988	Europe				
0 493 686 A1	07/1992	Europe				
0 867 190 A1	09/1998	Europe				
0 533 199 A2	03/1993	Europe				

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Ojima et al, Tohoku J. Exp. Med., 1998, Vol. 185, No. 2, pp 89-100
	Shitara et al, Cancer Immunol Immunother, 1993, Vol. 36, No. 6, pp 373-380
	Scott et al, Current Opinion in Immunology, 1997, Vol. 9, No. 5, pp 717-722
	Alpaugh et al, Medical Oncology, 1998, Vol. 15, No. 3, pp 191-198
	Nasi et al, Melanoma Research, 1997, Vol. 7, No. suppl 2, pp S155-S162
	Chapman et al, Cancer Immunol Immunother, 1994, Vol. 39, No. 3, pp 198-204
	Dippold et al, European Journal of Cancer, 1992, Vol. 28A, No. 10, pp 1605-1610
	A Process for the Production of Humanized Chimaeric Antibody, Current Opinion in Therapeutic Patents, 993, Vol. 3, No. 9, pp 1357-1358
	Supplementary European Search Report dated August 18, 2005 issued in corresponding EP 00 96 2981.7

*Examiner	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)